Che Leung Law

Summary

Affiliation: Seattle Genetics
Country: USA

Publications

  1. ncbi request reprint Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
    Julie A McEarchern
    Seattle Genetics, Inc, Bothell, WA 98021, USA
    Blood 109:1185-92. 2007
  2. ncbi request reprint Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
    Che Leung Law
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Cancer Res 66:2328-37. 2006
  3. doi request reprint Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges
    Che Leung Law
    Department of Preclinical Therapeutics, Seattle Genetics Inc, 21823 30th Drive SE, Bothell, Washington, 98021, USA
    Adv Exp Med Biol 647:8-36. 2009
  4. ncbi request reprint Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
    Che Leung Law
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Cancer Res 65:8331-8. 2005
  5. ncbi request reprint cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
    Joseph A Francisco
    Seattle Genetics, Bothell, WA 98021, USA
    Blood 102:1458-65. 2003
  6. ncbi request reprint Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates
    Che Leung Law
    Seattle Genetics, Inc, 21823 30th Drive Southeast, Bothell, WA 98021, USA
    Clin Cancer Res 10:7842-51. 2004
  7. ncbi request reprint Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
    Ezogelin Oflazoglu
    Department of Translational Biology, Seattle Genetics, WA 98021, USA
    Blood 110:4370-2. 2007
  8. doi request reprint Preclinical characterization of SGN-70, a humanized antibody directed against CD70
    Julie A McEarchern
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Clin Cancer Res 14:7763-72. 2008
  9. doi request reprint Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker
    Ezogelin Oflazoglu
    Department of Preclinical Therapeutics, Seattle Genetics Inc, 21823 30th Drive Southeast, Bothell, WA 98021, USA
    Clin Cancer Res 14:6171-80. 2008
  10. ncbi request reprint Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
    May S Kung Sutherland
    Department of Molecular Oncology and Immunology, Seattle Genetics Inc, 21823 30th Drive SE, Bothell, WA 98021, USA
    J Biol Chem 281:10540-7. 2006

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
    Julie A McEarchern
    Seattle Genetics, Inc, Bothell, WA 98021, USA
    Blood 109:1185-92. 2007
    ..These data suggest that an anti-CD70 antibody, when engineered to contain human IgG1 constant domains, possesses effector cell-mediated antitumor activity and has potential utility for anticancer therapy...
  2. ncbi request reprint Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
    Che Leung Law
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Cancer Res 66:2328-37. 2006
    ....
  3. doi request reprint Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges
    Che Leung Law
    Department of Preclinical Therapeutics, Seattle Genetics Inc, 21823 30th Drive SE, Bothell, Washington, 98021, USA
    Adv Exp Med Biol 647:8-36. 2009
    ..This chapter reviews the role of CD40-CD40L costimulation in disease pathogenesis, the characteristics of therapeutic agents targeting this pathway and status of their clinical development...
  4. ncbi request reprint Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
    Che Leung Law
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Cancer Res 65:8331-8. 2005
    ..The preclinical in vitro and in vivo antilymphoma activity of SGN-40 observed in this study provides a rationale for the clinical testing of SGN-40 in the treatment of CD40+ B-lineage lymphomas...
  5. ncbi request reprint cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
    Joseph A Francisco
    Seattle Genetics, Bothell, WA 98021, USA
    Blood 102:1458-65. 2003
    ..Mice treated at 30 mg/kg cAC10-vcMMAE showed no signs of toxicity. These data indicate that cAC10-vcMMAE may be a highly effective and selective therapy for the treatment of CD30+ neoplasias...
  6. ncbi request reprint Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates
    Che Leung Law
    Seattle Genetics, Inc, 21823 30th Drive Southeast, Bothell, WA 98021, USA
    Clin Cancer Res 10:7842-51. 2004
    ..These data indicate that anti-CD20-based antibody-drug conjugates are effective antitumor agents when prepared with a stable, enzyme-cleavable peptide linkage to highly potent cytotoxic agents such as MMAE...
  7. ncbi request reprint Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
    Ezogelin Oflazoglu
    Department of Translational Biology, Seattle Genetics, WA 98021, USA
    Blood 110:4370-2. 2007
    ..These findings may have implications for patient stratification or combination treatment strategies in clinical trials conducted with SGN-30 in HD and ALCL...
  8. doi request reprint Preclinical characterization of SGN-70, a humanized antibody directed against CD70
    Julie A McEarchern
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Clin Cancer Res 14:7763-72. 2008
    ..We developed a humanized anti-CD70 antibody, SGN-70, and herein describe the antitumor activities of this mAb...
  9. doi request reprint Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker
    Ezogelin Oflazoglu
    Department of Preclinical Therapeutics, Seattle Genetics Inc, 21823 30th Drive Southeast, Bothell, WA 98021, USA
    Clin Cancer Res 14:6171-80. 2008
    ..Here, we tested h1F6-maleimidocaproyl (mc) MMAF conjugates, consisting of an uncleavable mc linker, for their ability to interfere with the growth of CD70-positive carcinomas...
  10. ncbi request reprint Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
    May S Kung Sutherland
    Department of Molecular Oncology and Immunology, Seattle Genetics Inc, 21823 30th Drive SE, Bothell, WA 98021, USA
    J Biol Chem 281:10540-7. 2006
    ....
  11. pmc Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia
    May Kung Sutherland
    Department of Pre Clinical Therapeutics, Seattle Genetics, Inc, Bothell, WA, USA
    MAbs 1:481-90. 2009
    ..Given that lintuzumab induced meaningful responses in a phase 1 clinical trial, the preclinical antitumor activities defined in this study may underlie its observed therapeutic efficacy in AML patients...
  12. doi request reprint Targeting CD70 for human therapeutic use
    Tamar E Boursalian
    Department of Preclinical Therapeutics, Seattle Genetics, Inc, Bothell, Washington, USA
    Adv Exp Med Biol 647:108-19. 2009
    ..This chapter provides an overview of the physiological role of CD70-CD27 interactions and discusses various approaches to target this pathway for therapeutic use in cancers and autoimmunity...
  13. doi request reprint Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma
    Timothy S Lewis
    Department of Pre Clinical Research, Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Clin Cancer Res 17:4672-81. 2011
    ..We examined if the antitumor activity of rituximab, CD20-specific antibody, could be improved by simultaneously targeting CD40 with the humanized monoclonal antibody dacetuzumab (SGN-40)...
  14. doi request reprint The pharmacologic basis for antibody-auristatin conjugate activity
    Stephen C Alley
    Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, WA 98021, USA
    J Pharmacol Exp Ther 330:932-8. 2009
    ..The data establish the pharmacologic basis of activity of the ADC through specific tumor targeting, intratumoral auristatin retention, and ADC stability in the systemic circulation...
  15. pmc Development of orally active inhibitors of protein and cellular fucosylation
    Nicole M Okeley
    Seattle Genetics, Bothell, WA 98021
    Proc Natl Acad Sci U S A 110:5404-9. 2013
    ..The results point to several potential therapeutic applications for molecules that selectively block the endogenous generation of fucosylated glycan structures...
  16. doi request reprint Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia
    Che Leung Law
    Department of Preclinical Therapeutics, Seattle Genetics, Inc, Bothell, WA 98021, USA
    Clin Lymphoma Myeloma 9:90-3. 2009
    ..Indeed, early clinical trials with therapeutic anti-CD70 antibodies are currently in progress, and those for anti-CD70 drug conjugates will soon follow...
  17. ncbi request reprint Expression and characterization of recombinant soluble human CD3 molecules: presentation of antigenic epitopes defined on the native TCR-CD3 complex
    Che Leung Law
    Xcyte Therapies, Inc, Seattle, WA 98104, USA
    Int Immunol 14:389-400. 2002
    ....
  18. doi request reprint Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis
    Ezogelin Oflazoglu
    Department of Preclinical Therapeutics, Seattle Genetics, Bothell, Washington 98021, USA
    J Immunol 183:3770-7. 2009
    ....
  19. ncbi request reprint Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer
    Joseph Petroziello
    Department of Antibody Technologies, Seattle Genetics Inc, 21823 30th Drive SE, Bothell, WA 98021, USA
    Oncogene 23:7734-45. 2004
    ..Follow-up studies for candidate NSCLC-associated genes can be useful in providing valuable insight into the etiology of lung cancer as well as providing potentially interesting diagnostic or therapeutic targets for further investigation...
  20. ncbi request reprint Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus
    Frédéric Lajaunias
    Department of Pathology, University of Geneva, Geneva, Switzerland
    Arthritis Rheum 48:1612-21. 2003
    ..In this study, we investigated how the expression of CD22 ligand (CD22L) is modulated following lymphocyte activation or during the course of systemic lupus erythematosus (SLE)...